Biogen sees no need for big changes in wake of Alzheimer's drug setback

Biogen sees no need for big changes in wake of Alzheimer's drug setback

STAT Plus: Biogen sees no need for big changes in wake of Alzheimer’s drug setback

By ADAM FEUERSTEIN

RUBY WALLAU FOR STAT

Any investor hoping for a more radical adjustment to the biotech’s strategic plan following the aducanumab failure has to be disappointed.

READ MORE